RELIEF THERAPEUTICS Holding AG

Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs

Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who’ve Exhausted All Approved Therapies